PERCF (Percheron Therapeutics) EBIT per Share: $-0.01 (TTM As of Dec. 2025)


What is Percheron Therapeutics EBIT per Share?

Percheron Therapeutics PERCF -0.18% EBIT per Share is $-0.01 as of Dec. 2025. The stock has 2 warning signs investors should review. Among 809 Drug Manufacturers companies, Percheron Therapeutics ranks worse than 76.39% on this metric.

Percheron Therapeutics's EBIT per Share for the six months ended in Dec. 2025 was $-0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.01.

During the past 3 years, the average EBIT per Share Growth Rate was -10.10% per year. During the past 5 years, the average EBIT per Share Growth Rate was -3.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Percheron Therapeutics's EBIT per Share or its related term are showing as below:

PERCF' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -146.6   Med: 12.1   Max: 53.3
Current: -10.1

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Percheron Therapeutics was 53.30% per year. The lowest was -146.60% per year. And the median was 12.10% per year.

PERCF's 3-Year EBIT Growth Rate is ranked worse than
76.39% of 809 companies
in the Drug Manufacturers industry
Industry Median: 7.6 vs PERCF: -10.10

Percheron Therapeutics's EBIT for the six months ended in Dec. 2025 was $-2.06 Mil.

Percheron Therapeutics  (OTCPK:PERCF) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Percheron Therapeutics EBIT per Share Related Terms

Percheron Therapeutics EBIT per Share Historical Data

* Premium members only.

The historical data trend for Percheron Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Percheron Therapeutics EBIT per Share Chart

Percheron Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.01 -0.01 -0.01 -0.01 -0.01

Percheron Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.00 -0.01 -0.00 -0.00

Percheron Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Percheron Therapeutics's EBIT per Share for the fiscal year that ended in Jun. 2025 is calculated as

EBIT per Share(A: Jun. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-9.705/1051.404
=-0.01

Percheron Therapeutics's EBIT per Share for the quarter that ended in Dec. 2025 is calculated as

EBIT per Share(Q: Dec. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-2.056/1116.436
=-0.00

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of $-0.01 mean?
Percheron Therapeutics (PERCF) has a EBIT per Share of $-0.01 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Percheron Therapeutics and its competitors. According to the industry distribution chart, Percheron Therapeutics ranks #618 out of 809 companies in the Drug Manufacturers industry, placing it in the top 76.4%.
Is Percheron Therapeutics' EBIT per Share too high?
Percheron Therapeutics' current EBIT per Share is $-0.01. Based on the distribution chart, Percheron Therapeutics ranks #618 out of 809 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Percheron Therapeutics' EBIT per Share compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Percheron Therapeutics ranks #618 out of 809 companies for EBIT per Share. This places Percheron Therapeutics in the lower half of its industry. The industry median EBIT per Share is 7.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.60, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Percheron Therapeutics and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Percheron Therapeutics's current EBIT per Share is $-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Percheron Therapeutics stock overvalued right now?
Percheron Therapeutics (PERCF) has a current EBIT per Share of $-0.01. The current EBIT per Share is $-0.01. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Percheron Therapeutics (PERCF), the current EBIT per Share is $-0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Percheron Therapeutics Business Description

Other Exchanges AWY0:GermanyPER:Australia
Address 35 Collins Street, Level 30, Collins Place, Melbourne, VIC, AUS, 3000
Percheron Therapeutics Ltd is a biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The company operates into two operating segment: ATL1102 and ATL1103. Key revenue is generated from ATL1102.